Maximizing resources to study an uncommon cancer: E2C2—Epidemiology of Endometrial Cancer Consortium

被引:0
|
作者
Sara H. Olson
Chu Chen
Immaculata De Vivo
Jennifer A. Doherty
Virginia Hartmuller
Pamela L. Horn-Ross
James V. Lacey
Shannon M. Lynch
Leah Sansbury
V. Wendy Setiawan
Leo J. Schouten
Xiao Ou Shu
机构
[1] Memorial Sloan-Kettering Cancer Center,Department of Epidemiology and Biostatistics
[2] Fred Hutchinson Cancer Research Center,Program in Epidemiology, Division of Public Health Sciences
[3] University of Washington,Department of Epidemiology, School of Public Health and Community Medicine
[4] University of Washington,Department of Otolaryngology: Head and Neck Surgery, School of Medicine
[5] Brigham and Women’s Hospital,Channing Laboratory, Department of Medicine
[6] Harvard Medical School,Department of Epidemiology
[7] Harvard School of Public Health,Epidemiology & Genetics Research Program, Division of Cancer Control and Population Sciences
[8] National Cancer Institute,Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics
[9] Northern California Cancer Center,Department of Preventive Medicine, Keck School of Medicine
[10] National Cancer Institute,Department of Epidemiology, GROW – School for Oncology and Developmental Biology
[11] University of Southern California,Vanderbilt Epidemiology Center
[12] Maastricht University,Department of Medicine
[13] Vanderbilt Institute of Medicine and Public Health,undefined
[14] Vanderbilt University Medical Center,undefined
[15] Vanderbilt-Ingram Cancer Center,undefined
来源
Cancer Causes & Control | 2009年 / 20卷
关键词
Endometrial cancer; Epidemiology;
D O I
暂无
中图分类号
学科分类号
摘要
Endometrial cancer affects more than 40,000 women a year in the U.S. While the association of this disease with high body mass index and sex steroid hormones is well known, there are many questions about etiology that have not been resolved. Little is known about the genetic basis for risk associated with hormones or obesity, other common genetic factors associated with risk, or gene–environment interactions. E2C2, the Epidemiology of Endometrial Cancer Consortium, was formed in 2006 to provide a collaborative environment for addressing these questions by pooling data from existing studies. This allows for investigations of uncommon risk factors, risk for rare histologic subtypes, and associations within strata that cannot be achieved in individual studies. This report describes the establishment of the consortium, ongoing projects that demonstrate the advantages of collaborative efforts, and challenges faced. Overall, the consortium promises to provide an important means of furthering our knowledge about this cancer.
引用
收藏
页码:491 / 496
页数:5
相关论文
共 50 条
  • [21] MSH2 splice site mutation and endometrial cancer
    Bianchi, F.
    Rosati, S.
    Belvederesi, L.
    Loretelli, C.
    Catalani, R.
    Mandolesi, A.
    Bracci, R.
    Bearzi, I.
    Porfiri, E.
    Cellerino, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (03) : 1419 - 1423
  • [22] Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan
    Tseng, Chin-Hsiao
    GYNECOLOGIC ONCOLOGY, 2015, 138 (01) : 147 - 153
  • [23] Prognostic significance of Matrix Metalloproteinases 2 and 9 in Endometrial Cancer
    Puljiz, Mario
    Puljiz, Zeljko
    Vucemilo, Tiha
    Ramic, Snjezana
    Knezevic, Fabijan
    Culo, Branimir
    Alvir, Ilija
    Tomica, Darko
    Danolic, Damir
    COLLEGIUM ANTROPOLOGICUM, 2012, 36 (04) : 1367 - 1372
  • [24] Aberrant expression of UBE2C in endometrial cancer and its correlation to epithelial mesenchymal transition
    Zhang, Yan
    Li, Xueting
    Gong, Yingying
    Du, Danli
    Chen, Huilei
    Liu, Lei
    Cheng, Zenong
    MEDICINE, 2023, 102 (20) : E33834
  • [25] Combination analysis of Bub1 and Mad2 expression in endometrial cancer: act as a prognostic factor in endometrial cancer
    Li, Lin
    Xu, De-Bin
    Zhao, Xiao-Li
    Hao, Tian-Yu
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 288 (01) : 155 - 165
  • [26] Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study
    Pla-Juher, Helena
    Pardo, Marta
    Izquierdo, Angel J.
    Darder, Esther
    Carbo, Anna
    Munte, Elisabet
    Torres-Esquius, Sara
    Balmana, Judith
    Lazaro, Concepcion
    Brunet, Joan M.
    Barretina-Ginesta, Maria-Pilar
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (04) : 1033 - 1037
  • [27] Stanniocalcin-2 May Be a Potentially Valuable Prognostic Marker in Endometrial Cancer: a Preliminary Study
    Aydin, Hulya Ayik
    Toptas, Tayfun
    Bozkurt, Selen
    Aydin, Armagan
    Erdogan, Gulgun
    Pestereli, Elif
    Simsek, Tayup
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (02) : 751 - 757
  • [28] CDK4/RB/E2Fs axis as potential therapeutic target of endometrial cancer
    Hu, Jing
    Shen, Junwei
    Sun, Jing
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 125
  • [29] Combination analysis of Bub1 and Mad2 expression in endometrial cancer: act as a prognostic factor in endometrial cancer
    Lin Li
    De-Bin Xu
    Xiao-Li Zhao
    Tian-Yu Hao
    Archives of Gynecology and Obstetrics, 2013, 288 : 155 - 165
  • [30] Type 2 Diabetes Mellitus and Cancer: Epidemiology, Physiopathology and Prevention
    Rey-Renones, Cristina
    Baena-Diez, Jose Miguel
    Aguilar-Palacio, Isabel
    Miquel, Cristina
    Grau, Maria
    BIOMEDICINES, 2021, 9 (10)